Premium
Adjuvant chemotherapy (CMF) for breast carcinoma: Hematological side effects
Author(s) -
Lee Yeutsu N.Margaret
Publication year - 1982
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930210303
Subject(s) - leukopenia , medicine , dose , chemotherapy , adjuvant , breast carcinoma , gastroenterology , surgery , breast cancer , cancer
Seventy‐five patients accepted postmastectomy adjuvant CMF chemotherapy for stage II and III carcinoma of the breast. All patients, irrespective of age, were started on the same drug dosages. About 42% of the patients had leukopenia during the first two cycles; this rate was similar for patients who dropped out of the program early and those who stayed on for six or more months. Patients who developed leukopenia early are more likely to receive less than 65% of mean total CMF dosages (MTD). Otherwise, 30% of patients that never had leukopenia or had leukopenia that appeared late received more than 85% of the prescribed CMF. In our series, postmenopausal patients did not have more problem with leukopenia than premenopausal patients (thrombocytopenia occurred rarely in both groups). Among the 58 patients who had CMF for 6 months or longer, 79% had less than 85% MTD of CMF. The dosages had to be reduced for drug‐related and other reasons, and leukopenia only accounted for 22% of patients who had reduced CMF dosages.